Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date of Conference**: March 02, 2026 - **Key Personnel**: COO Mark Jacobson, CFO Nick Pizzie Core Business and Financial Performance - **AUVELITY Performance**: Generated $155 million in the last quarter, annualizing over $600 million after 13 quarters from launch [3][4] - **Sales Force Expansion**: Plans to increase field force from 300 to 600 representatives to enhance market penetration, particularly in anticipation of Alzheimer's disease agitation [3][4] - **Operating Leverage**: Revenues outpaced operating expenses by a ratio of 3:1 in 2025, with expectations for continued leverage in 2026 [4] Product Pipeline and Development - **Robust Pipeline**: Currently has 5 product candidates across 9 indications, with AXS-05 for Alzheimer's disease agitation being a key focus [5] - **PDUFA Date**: AXS-05 has a PDUFA date set for April 30, 2026, with pre-launch activities already underway [5][12] - **Clinical Trials**: Positive results from randomized withdrawal studies and head-to-head placebo-controlled studies for AXS-05, with significant safety data collected [15][16] Market Insights - **Market Penetration**: Currently at 0.2% of the total antidepressant market, indicating substantial growth potential [8] - **Patient Demographics**: Over 7 million Alzheimer's patients in the U.S., with an estimated 70% experiencing agitation, representing a significant treatment opportunity [20] - **Direct-to-Consumer Campaign**: Launched a national DTC campaign in September, with plans to continue through 2026, aiming to enhance product adoption [10][11] Competitive Landscape - **Comparison with Rexulti**: Acknowledged as the only approved product for Alzheimer's agitation, but differences in mechanism and sales strategy noted [31][32] - **Market Access**: Anticipated 100% coverage in government channels for Alzheimer's agitation, similar to MDD, which could facilitate script writing [34] Additional Products and Future Opportunities - **Simbravo Launch**: Targeted approach with a sales team focused on headache centers, showing early positive feedback [35][36] - **AXS-12 for Narcolepsy**: NDA submission expected soon, with peak sales potential estimated between $500 million to $1 billion [40][42] - **Sunosi Expansion**: Positive Phase 3 data in adult ADHD, with plans for pediatric studies, indicating a significant market opportunity [43][44] - **AXS-14 for Fibromyalgia**: Currently conducting a new study following an RTF from the FDA, with expectations for compelling data in an underserved market [51][53] Conclusion - Axsome Therapeutics is positioned for significant growth with a robust pipeline and strategic expansions in sales force and market access. The upcoming PDUFA date for AXS-05 and ongoing clinical trials for other products highlight the company's commitment to addressing unmet medical needs in various therapeutic areas.

Senti Biosciences (NasdaqCM:SNTI) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsEllen Horste - Equity Research AssociateKanya Rajangam - President, Head of Research and Development, and Chief Medical OfficerTimothy Lu - Co-Founder and CEOConference Call ParticipantsPhil Nadeau - Managing Director and Research AnalystNone - AnalystEllen HorsteAfternoon, welcome back to TD Cowen's 46th Annual Healthcare Conference. I'm Ellen Horste, TD Cowen Biotech Associate. On behalf of Phil Nadeau's team, I ...

Summary of Eli Lilly's Conference Call Company Overview - **Company**: Eli Lilly - **Event**: 46th Annual Healthcare Conference - **Key Representatives**: Lucas Montarce (CFO), Mike Czapar (Head of Investor Relations) Core Industry and Product Insights Orforglipron - **Regulatory Approval**: Eli Lilly is on track for regulatory approval of orforglipron, expected in early Q2 2024, with a full commercial launch planned shortly after [4][6] - **Market Access**: Anticipated broad access for orforglipron in Medicare starting July 1, 2026, with a starting price of $149, scaling up to $399 [6][10] - **Patient Demand**: There is a significant patient population seeking oral treatments over injectables, which orforglipron aims to address [9][12] - **Market Dynamics**: The product is expected to drive market expansion, particularly in the U.S., with a focus on patients with a BMI of 30+ [16][19] Competitive Landscape - **Comparison with Wegovy**: Orforglipron is expected to compete favorably against Wegovy, with a focus on its oral administration profile [9][10] - **Market Leadership**: Eli Lilly aims to capture market share from competitors, leveraging the convenience of orforglipron [10][12] Financial Projections - **Pre-launch Inventory**: Eli Lilly holds approximately $1.5 billion in pre-launch inventory for orforglipron, but this is not directly correlated with 2026 revenue forecasts [18] - **Revenue Growth**: The company is optimistic about revenue growth from orforglipron, with expectations for market expansion over time [18][19] Product Portfolio and Future Prospects Key Assets - **Ranking of Products**: The key assets include Zepbound, Mounjaro (orforglipron), and retatrutide, with tirzepatide seen as foundational for obesity and diabetes treatment [20][24] - **Retatrutide**: Expected to target a specific patient population with significant weight reduction potential [26] Pipeline and Therapeutic Areas - **Expansion into Cardiovascular**: Eli Lilly is entering the cardiovascular space with new assets that could significantly impact patient care [42] - **Oncology Developments**: The company has ongoing trials for oral SERDs in oncology, which are projected to read out by 2027 [44] Market Opportunities Global Reach - **U.S. vs. Ex-U.S. Market**: There are over 900 million potential patients outside the U.S. for incretin medicines, with the U.S. market also showing significant potential [30][31] - **Launch Timing**: The company expects to reduce the lag time between U.S. and international launches, particularly in China [59][60] Risks and Challenges Pricing and Market Concentration - **Pricing Pressures**: Pricing remains a headwind for the industry, but Eli Lilly is focused on innovation to offset price erosion [36][37] - **Portfolio Concentration**: While there is a concentration in obesity and diabetes, the company is committed to diversifying its portfolio across therapeutic areas [38][39] Regulatory and Competitive Landscape - **Compounding Concerns**: Eli Lilly is actively addressing compounding issues and is confident in the health of its business [41] Technological Innovations AI Integration - **AI in Operations**: Eli Lilly is leveraging AI to enhance efficiency in various operations, including SG&A and manufacturing [66] Conclusion - **Future Growth**: Eli Lilly anticipates significant growth over the next decade, driven by its expanding product portfolio and entry into new therapeutic areas [70][71]

Summary of Vir Biotechnology FY Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus**: Development of innovative therapies for serious diseases, particularly in oncology and infectious diseases Key Developments - **VIR-5500**: - Recent data disclosed showed impressive efficacy and safety profiles in a trial involving very sick patients, with 95% having pre-taxane treatment and a median of 4 prior therapies [2][3] - **Efficacy Metrics**: - PSA50 rate: 82% - PSA90 rate: 53% - PSA99 rate: 29% - RECIST ORR: 45% in a very sick patient population [4] - **Safety Profile**: - Utilizes a PRO-XTEN masking platform to enhance safety by activating T-cells only at the tumor site, allowing for higher dosing without significant toxicity [5][6] Partnership with Astellas - **Strategic Partnership**: - Astellas selected as a partner due to their experience in prostate cancer and alignment on speed to market [16][17] - The deal includes a 50/50 profit split and a total of $1.7 billion in milestones, with $240 million cash upfront [19] - Vir retains significant involvement in the program, allowing for cash flow to support other projects [18] Future Plans - **Expansion Cohorts**: - Plans to initiate expansion cohorts for late-line monotherapy and early-line combination therapies with enzalutamide [11] - Pivotal trials expected to start next year [11] Competitive Landscape - **T-cell Engagers (TCEs)**: - VIR-5500 positioned as a potential best-in-class TCE for prostate cancer, achieving a favorable balance of efficacy and safety compared to competitors [13] - Other TCEs have shown either high efficacy with toxicity issues or mediocre efficacy with good safety profiles [13] Pipeline Overview - **Clinical Assets**: - Licensed three clinical-stage assets from Sanofi, including HER2 (VIR-5818) and EGFR (VIR-5525), both in phase 1 [23] - Seven preclinical assets utilizing the PRO-XTEN technology are progressing rapidly [24] Hepatitis Delta Virus (HDV) Program - **Tobevibart and Elebsiran**: - Combination therapy showed an 88% target not detected rate after 96 weeks, indicating strong efficacy in treating HDV [30] - Registrational trials ongoing, with initial data expected in Q4 2026 [30] Market Opportunity - **HDV Patient Population**: - Estimated 60,000 viremic patients in the U.S. and double that in Europe, with high potential pricing due to the orphan disease status [34] - Pricing estimates range from $150K to $250K in the U.S. and €60,000 to €150,000 in Europe [34] Financial Position - **Cash Balance**: - Post-Astellas deal, cash balance is $783 million, extending runway into Q2 2028 [37] - Recent equity raise of $173 million to support TCE portfolio [37] Strategic Considerations - **Internal vs. External Development**: - Decisions made on a case-by-case basis, considering market size, competitive landscape, and required capabilities [39][40] Conclusion - Vir Biotechnology is positioned strongly in the oncology space with promising data for VIR-5500 and a strategic partnership with Astellas that enhances its development capabilities and financial flexibility. The company is also making significant strides in addressing unmet needs in HDV treatment, with a robust pipeline and a clear strategy for future growth.

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory & Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments Drug Development and Mechanism - PALI-2108 is a prodrug formulation that releases its active ingredient in the lower gastrointestinal (GI) tract, avoiding adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events like headache and nausea [3][4] - The drug has shown efficacy in treating IBD diseases, with a focus on reducing adverse events by localizing the drug's action [3][4] Clinical Trials and Milestones - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients in a Phase 1b cohort [4][5] - A small cohort study in fibrostenotic Crohn's disease is expected to read out by the end of March 2026 [5] - Plans to file an Investigational New Drug (IND) application for ulcerative colitis in May 2026, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] Market Potential - Crohn's disease and ulcerative colitis are identified as multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself by being the first dual-acting anti-inflammatory and anti-fibrotic drug in development for fibrostenotic Crohn's disease [11][14] Competitive Landscape - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company is developing a precision medicine test to identify potential responders to PALI-2108, enhancing its competitive edge [12][19] Financial Overview - Completed a transformational financing in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [28][29] - The company maintains a clean capital structure with 206 million shares fully diluted [28][29] Key Insights and Considerations - The drug's design aims to minimize common PDE4-related adverse events, which could enhance its market acceptance [43][44] - The company emphasizes its capital efficiency and execution capabilities, which may be underappreciated in the market [47][48] - There is ongoing evaluation regarding whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, pending data from the Phase 1b cohort [31][33] Conclusion Palisade Bio is positioned in a promising niche within the biotechnology sector, focusing on innovative oral therapeutics for IBD. The company's strategic development of PALI-2108, along with its financial backing and market potential, presents a compelling case for investors looking for opportunities in the healthcare space.

Summary of Backblaze Conference Call Company Overview - **Company**: Backblaze - **Industry**: Cloud Storage and Data Management - **Recent Developments**: Backblaze reported its fourth-quarter results, reflecting significant changes and progress since its IPO in 2021 Key Financial Metrics - **Revenue Growth**: Revenue growth improved from 21% to 24% year-over-year, with a free cash flow margin increasing from -13% to +11% [4][5] - **Rule of 40 Score**: Increased from 9% to 35% within a year, indicating improved financial health [5] - **Customer Growth**: The company aims to stabilize its customer base in the computer backup segment, which currently has a churn rate of about 10% [10] Product Developments - **B2 Cloud Storage**: The primary growth driver for Backblaze, with expectations for faster growth and healthier economics [6] - **Computer Backup Product**: New features like Advanced Installer and Command Line Interface aimed at attracting Managed Service Providers (MSPs) [8] - **B2 Neo**: A white-label service for Neocloud providers, contributing to the largest Total Contract Value (TCV) deal to date [13] - **Market Opportunity**: The Neocloud market is expected to grow at 46% annually, representing a $14 billion opportunity for Backblaze [14] Market Dynamics - **Neocloud Providers**: Many existing solutions are open-source and lack reliability, creating opportunities for Backblaze to offer superior storage solutions [16] - **Competitive Landscape**: Backblaze's performance metrics, such as eleven nines of durability, position it favorably against competitors [16] Sales and Marketing Strategy - **Go-to-Market Transformation**: Aiming to double the sales pipeline from $15 million in 2024 to $60 million by 2026 [48] - **Sales Cycle**: Larger deals (over $500K in ARR) have longer sales cycles due to increased complexity, leading to their exclusion from forward guidance [56] - **Pipeline as an Indicator**: The health of the sales pipeline is viewed as a leading indicator of success, with a focus on both new customer acquisition and expansion within existing accounts [62] Future Outlook - **Expansion Plans**: The company is focused on building a repeatable sales process to capture larger deals while maintaining growth in smaller accounts [60] - **Performance Metrics**: Emphasis on tracking metrics related to advertising effectiveness, site visits, and conversion rates to ensure pipeline growth [62] Additional Insights - **Diversity of Offerings**: Backblaze serves a variety of workloads, including backup, archiving, and live storage, which contributes to its customer base of 119,000 self-serve users [35] - **Brand Repositioning**: The launch of B2 Overdrive has helped re-anchor Backblaze's brand as a high-performance platform, enhancing its market presence [42] This summary encapsulates the key points discussed during the conference call, highlighting Backblaze's financial performance, product developments, market opportunities, and strategic initiatives.

Summary of The Macerich Company 2026 Conference Call Company Overview - **Company**: The Macerich Company (NYSE: MAC) - **Event**: Citi's 2026 Global Property CEO Conference - **Date**: March 02, 2026 - **Key Speakers**: Jack Hsieh (CEO), Dan Swanstrom (CFO), Brad Miller (SVP, Asset Management) Core Industry Insights - **Leasing Performance**: In 2025, Macerich signed 7.1 million square feet of new and renewal leases, an 85% increase over 2024, setting a new company record [6] - **Leasing Speedometer**: The leasing speedometer is at 76%, ahead of the 70% target for year-end, with expectations to reach 85% by mid-2026 [6] - **Signed Not Open (SNO) Pipeline**: The SNO pipeline reached $107 million, exceeding the $100 million target, with projections of incremental contributions of $30 million in 2026, $40-$45 million in 2027, and $45-$50 million in 2028 [7] - **Anchor Replacements**: All 30 targeted anchor and big box replacements are committed, expected to generate over $750 million in annual tenant sales [7] Financial Highlights - **Portfolio Sales**: Portfolio sales reached $921 per square foot, a new high since the IPO in 1994 [8] - **Positive Leasing Spreads**: The company has posted 17 consecutive quarters of positive leasing spreads [8] - **NOI Growth**: Expected at least 3% growth for the go-forward portfolio in 2026, with acceleration in 2027 and 2028 due to new leasing activity and redevelopment projects [11] Strategic Focus Areas - **Path Forward Plan**: The company is focused on completing a leasing pipeline of 350 additional new leases, solidifying lease expirations, and evaluating new acquisition opportunities [12] - **De-leveraging**: The company is in a de-leveraging stage, with a goal to reduce debt-to-EBITDA to the low- to mid-6 times range [29] - **Acquisition Strategy**: Future acquisitions will be opportunistic and must align with the 2028 objectives, focusing on properties that enhance the portfolio without jeopardizing current plans [19][30] Operational Improvements - **Technology Integration**: The company has improved internal processes and technology, utilizing Yardi for accounting and tracking, which has enhanced efficiency in leasing operations [40][41] - **AI Utilization**: Currently exploring AI applications for lease intelligence and energy efficiency, with potential future applications for market analysis and tenant selection [53][55] Market Outlook - **Retail Demand**: Demand remains strong across various sectors, including traditional retail, international brands, food and beverage, and entertainment [9] - **Future Projections**: The company anticipates continued positive growth in same-store and online retail for 2027, comparable to the last 12 months [63][66] Additional Insights - **Tenant Relationships**: Tenants appreciate the clarity and speed of decision-making from Macerich, which has improved their confidence in investing in the centers [50][52] - **Operational Efficiency**: The company is focused on controlling expenses and maximizing utility efficiency, especially in light of vacancy [61] This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic direction, financial performance, and market outlook.

Summary of Essex Property Trust Conference Call Company Overview - Essex Property Trust is an S&P 500 company with over 63,000 units, focused solely on the West Coast of the United States as a public apartment REIT [2] - The company has a strong track record of delivering one of the best long-term compound annual growth rates (CAGRs) and total returns in the REIT sector, marking its 32nd consecutive year of dividend increases [2] Industry Insights - The California housing market is characterized by low supply, currently at a historical low of about 0.5% of total housing stock, which includes single-family homes [3] - Demand catalysts, particularly from the technology sector in Northern California, are expected to continue driving job growth, especially with the rise of artificial intelligence (AI) [3][4] Investment Thesis - The company is still in a recovery phase post-COVID, with Northern California markets like Santa Clara and San Jose only beginning to recover in 2024, and San Francisco in 2025 [4] - Essex's unique operating platform allows for economies of scale, leading to better expense management compared to peers [4] Regulatory Environment - While regulatory challenges exist in California, the stable political environment post-November elections is seen as beneficial for the company [6][8] - The current regulatory landscape is not perceived as extreme, and the company does not foresee significant public policy changes that would negatively impact operations [8] Job Market and AI Impact - The job market remains resilient, with low unemployment claims, indicating that job losses are being quickly absorbed by new job creation, particularly in AI sectors [9] - AI is expected to be a net neutral or positive contributor to job growth in the near term, with significant demand for developers and new startups emerging [9][11] Market Performance and Pricing - Essex is currently seeing pockets of strength in Northern California and parts of Seattle, with occupancy rates slightly ahead of plan [16] - The company is negotiating lease renewals around 4% but landing closer to mid-to-high 3% depending on the market conditions [17][21] Southern California Market - Southern California is expected to be the lowest performing market for Essex this year, with occupancy rates needing to exceed 95% to gain pricing power [29] - The market is still recovering from delinquency issues tied up in the courts, which are slower than historical norms [29] Seattle Market Commitment - Despite its volatility, Seattle is viewed as a long-term growth market due to strong demand catalysts, particularly from the technology sector [37][38] Capital Allocation Strategy - Essex has acquired over $2 billion in assets over the past two years, focusing on accretive investments [40][41] - The company is open to stock buybacks if they present a more compelling investment opportunity compared to acquisitions [42] Preferred Equity and Returns - The company expects to face headwinds from preferred equity this year but anticipates these will not carry forward into 2027 [60] - Future growth in the preferred equity book will depend on achieving the right risk-adjusted returns [61] Sector Outlook - The overall apartment sector is projected to see same-store and operating income growth of about 2% in 2027 [66] - The number of public apartment companies is expected to remain the same or decrease, largely due to challenges in the Sun Belt markets [68] AI Integration - Essex is piloting AI capabilities in leasing and data analytics, aiming to drive efficiencies and improve processes [54][59] - The company acknowledges that while many firms are experimenting with AI, the adoption rate remains low, and success will depend on how effectively AI is integrated into business operations [57]

Summary of W. P. Carey Conference Call Company Overview - **Company**: W. P. Carey - **Type**: Net lease REIT - **Market Cap**: Approximately $16 billion - **Enterprise Value**: Approximately $25 billion - **History**: Over 50 years in operation - **Investment Activity**: Continued strength in investment activity, with a record year for deal volume in 2025 and strong momentum into 2026 [2][3] Key Points Investment Activity and Growth - **Record Deal Volume**: Achieved over $3 billion in investments over the past five quarters, indicating strong activity in the U.S. net lease sector [8][10] - **Funding Position**: Over $900 million of unsettled equity forwards, effectively pre-funding 2026 investment volume [3] - **Portfolio Strength**: One of the best rent growth profiles in the net lease sector, contributing significantly to expected earnings growth [3] Earnings Guidance - **AFFO Guidance**: Initial guidance set at a conservative 4.2% growth, with potential for upward revision as tenant credit improves [12][22] - **Credit Loss Assumptions**: Starting with a cushion of $10 million-$15 million for potential credit loss, equating to 60-90 basis points of rent [12][15] Market Conditions - **Cap Rates**: Targeting cap rates generally in the mid-sevens, with expectations of slight compression due to stable interest rates [28][32] - **Competition**: The U.S. net lease market is competitive, with 27 public REITs targeting similar assets, particularly in retail [35][36] Portfolio Composition - **Retail Exposure**: Currently 22% of the portfolio by ABR, with a focus on opportunistic deals in the U.S. retail space [43][44] - **Industrial Focus**: Approximately 75% of deal volume over the last five years has been in industrial properties, primarily sourced through sale-leasebacks [36][41] Strategic Initiatives - **AI Utilization**: Investments in AI to enhance operational efficiency and improve underwriting processes [69][71] - **Carey Tenant Solutions**: Aimed at enhancing relationships with tenants and increasing follow-on investments, potentially adding $100 million-$200 million in deal flow annually [76][78] Risk Management - **Tenant Exposure**: Ongoing reduction of exposure to underperforming tenants, such as Hellweg, with plans to replace them with stronger operators [90][92] Investor Relations - **Valuation Concerns**: The company trades at a discount compared to peers, attributed to concerns over recurring deal volume and growth consistency [55][59] - **Total Shareholder Return**: Targeting a double-digit total shareholder return through growth and dividend yield [58] Additional Insights - **European Market**: Increased activity in Europe, with a more favorable competitive landscape and wider spreads compared to the U.S. [84][86] - **Long-term Strategy**: Focus on maintaining a diversified portfolio while simplifying operations to enhance growth potential [61][65]

Cogent Communications FY Conference Summary Company Overview - **Company**: Cogent Communications (NasdaqGS:CCOI) - **Industry**: Connectivity Services - **Global Reach**: Operates in 1,900 data centers across 57 countries, handling approximately 25% of the world's Internet traffic [3][4] Key Points and Arguments 1. Return to Organic Growth - Cogent has returned to organic top-line growth after experiencing a decline due to the acquisition of Sprint Global Markets Group from T-Mobile. The company had previously grown organically at over 10% annually for 18 years without M&A. The recent average revenue growth is now on a positive trajectory despite the decline from the Sprint customer base [6][6] 2. Margin Expansion - The company expanded its EBITDA margins by 800 basis points year-over-year, primarily through cost-cutting and an increase in high-margin on-net services. The revenue mix has shifted back to 61% on-net and 39% off-net from a previous low of 47% on-net [7][7] 3. Balance Sheet Concerns - Cogent's leverage increased to 6.6 times net leverage due to capital expenditures related to the Sprint acquisition. The company reduced its dividend policy by 98% to deleverage, having historically returned nearly $2 billion to shareholders through buybacks and dividends [8][8] 4. Debt Management Strategy - Plans to refinance unsecured debt with secured debt are in place. The company aims to remove $569 million of senior secured debt from the balance sheet, enhancing credit quality and providing more financing flexibility [10][12] 5. Data Center Strategy - Cogent is converting 125 of the 482 facilities acquired from Sprint into marketable data centers, investing $100 million primarily in the largest facilities. A new non-binding letter of intent for the sale of 10 data centers is expected to yield substantially more proceeds than a previous offer of $144 million for 2 facilities [20][21][16] 6. Future Financial Flexibility - The restructuring aims to enhance credit quality and provide the company with the ability to raise additional secured and unsecured debt. The anticipated debt coverage ratio will be above 2, with secured leverage projected at approximately 3.9 times on a forward basis [12][14] 7. EBITDA and Financial Reporting - The restructuring will not visibly change reported EBITDA at the public company level, as the changes involve intercompany payments. The focus remains on enhancing the capital structure and reducing costs of capital [31][31] Additional Important Information - The company has faced EBITDA headwinds due to declining payments from T-Mobile, impacting headline EBITDA numbers. Despite this, underlying EBITDA grew by $70 million year-over-year [48][48] - The IPv4 assets currently under asset-backed securitization will remain in the infrastructure group, while other addresses will stay within the main group [49][49] This summary encapsulates the critical insights from the Cogent Communications FY Conference, highlighting the company's strategic direction, financial health, and operational adjustments in the connectivity services industry.